World Cell and Gene Therapy Summit South Korea Grand Hyatt Incheon, Incheon

South Korea is rapidly advancing its cell and gene therapy (CGT) ecosystem, with key milestones such as Curocell’s Rimqarto becoming the first MFDS-approved cell therapy, and continued innovation from companies like Vaxcellbio and Rznomics advancing next-generation modalities. More recently, breakthroughs in in vivo CAR therapies, enhanced LNP and AAV delivery platforms, and advanced manufacturing have accelerated development timelines in the clinic.

The inaugural World Cell and Gene Therapy Summit South Korea unites international and local industry experts to share insights into better understanding of cellular microenvironments and gene editing tools. From T-Cells, NK cells, macrophages, and stem cells, the agenda will explore how different cell types are being harnessed to combat oncology, autoimmune diseases and beyond.

As part of the World Advanced Therapeutics Summit by Hanson Wade, this event offers a platform to connect with leaders across cell, gene and RNA therapies working to establish South Korea as a global hub for advanced biopharma innovation.